Calliditas Therapeutics' 2023 Annual Report PublishedUSA - EnglishUSA - English

STOCKHOLM, April 24, 2024 — Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX**) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website:** www.calliditas.com

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected]

This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was sent for publication, through the agency of the contact persons set out above, on April 24, 2024, at 7:00 p.m. CET.

About Calliditas

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT). Visit Calliditas.com for further information.

https://mb.cision.com/Main/16574/3967336/2758238.pdf

Calliditas Annual Report 2023

https://mb.cision.com/Public/16574/3967336/9a2538e7ee7d898d.pdf

Annual Report 2023 Eng

Fallback image

21%

more press release views with